Clinical Trials in Freiburg im Breisgau, Baden-Wurttemberg
1 recruiting
Showing 1–8 of 8 trials
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
Prostate CancerNon-metastatic Castration-resistant Prostate CancerBiochemical Recurrence of Malignant Neoplasm of Prostate
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled193 locationsNCT05827081
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie252 enrolled55 locationsNCT06772623
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
Breast Cancer (Early Breast Cancer)Advanced/Metastatic Breast Cancer
University Hospital Tuebingen13,500 enrolled61 locationsNCT02338167
Recruiting
Phase 2
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Lung Cancer Non-Small Cell Cancer (NSCLC)
University Hospital, Bonn176 enrolled5 locationsNCT06810609
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled30 locationsNCT06726148
Recruiting
Phase 3
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
West German Study Group348 enrolled42 locationsNCT06081244